Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Lutetium-177-PSMA ([177Lu]-PSMA-617), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling targeted radiation therapy to metastatic prostate lesions. Our objective was to retrospectively analyze the activity of [177Lu]-PSMA-617 given off-tria...

Full description

Bibliographic Details
Main Authors: Moran Gadot, Tima Davidson, Margalit Aharon, Eshetu G. Atenafu, Avraham Malki, Meital Levartovsky, Akram Saad, Liran Domachevsky, Raanan Berger, Raya Leibowitz
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
Lutetium
theranostics
prostate cancer
mCRPC
Online Access:https://www.mdpi.com/2072-6694/12/5/1078

Internet

https://www.mdpi.com/2072-6694/12/5/1078

Similar Items